This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da) and b) a mucoadhesive in polymer. Alternatively, composition may comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. Furthermore, the composition may further comprise one or more drugs. Also provided are methods of manufacturing and administering the compositions described herein, which are used as biodegradable, injectable mucoadhesive low-viscosity pastes.

This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits in patients infected with SARS-CoV-2 (the virus that causes COVID-19). The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically. The hemp oil is micellized with a median particle size of 22 nm in diameter, which considerably increases intestinal absorption, resulting in higher potency and a more rapid onset of action. Taken regularly, the preparation helps improve sleep quality by lengthening the time spent in deep sleep. In patients with COVID, the improved sleep quality is accompanied by a lower risk of cytokine storm.

The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upon storage for ameliorated use in treating or preventing disorders related to kinin formation.

The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upon storage for ameliorated use in treating or preventing disorders related to kinin formation.

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.

Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract and further includes propylene glycol and sodium chloride.

Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract and further includes propylene glycol and sodium chloride.

Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.

Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.